Key result
Levosimendan in refractory post-MI cardiogenic shock is linked to a ~43% higher cardiac index.
Why the study?
Although levosimendan improves hemodynamic function in acute exacerbation of congestive heart failure, its hemodynamic effects after ineffective conventional catecholamine therapy in cardiogenic shock following myocardial infarction needed to be determined.
Does levosimendan improve hemodynamic parameters in patients with persisting cardiogenic shock following acute myocardial infarction despite conventional therapy?
Observational (n=56)
No
Does levosimendan improve hemodynamic parameters in patients with persisting cardiogenic shock following acute myocardial infarction despite conventional therapy?
Levosimendan safely improves cardiovascular hemodynamics without causing hypotension in patients with cardiogenic shock complicating acute myocardial infarction who are unresponsive to conventional catecholamines.
Answers are grounded in this paper and cite their sources.
May support levosimendan for hemodynamics in refractory post-MI shock; hypothesis-generating and requires randomized confirmation before practice change.
Objectives Levosimendan, a novel inodilator, has been shown to improve hemodynamic function in patients with acute exacerbation of congestive heart failure. We wanted to determine the hemodynamic effects of levosimendan following ineffective conventional therapy (with catecholamines) in patients with cardiogenic shock following myocardial infarction. Design Observational hemodynamic study. Setting Tertiary care center university hospital. Patients Fifty-six patients with cardiogenic shock secondary to myocardial infarction were treated with percutaneous revascularization (intra-aortic balloon pump where appropriate) and commenced on conventional inotropic therapy. Interventions Patients with persisting cardiogenic shock 24 hrs after revascularization were additionally treated with levosimendan (rapid bolus of 12 microg/kg for 10 mins, then 0.05-0.2 mug/kg/min for 24 hrs) (n = 25). Measurements and main results With conventional catecholamine therapy (norepinephrine and dobutamine), we observed only marginal improvement in mean arterial pressure or cardiac index. In contrast, the addition of levosimendan produced a significant increase in cardiac index (2.1 +/- 0.56 to 3.0 +/- 1.11 L/min/m2, p < .01) and cardiac power index (0.32 +/- 0.08 to 0.44 +/- 0.18 W, p < .01), whereas systemic vascular resistance decreased significantly (1208 +/- 333 to 858 +/- 299 dyne.sec.cm(-5), p < .01). There was no significant change in blood pressure during levosimendan treatment. Hemodynamic improvement was sustained after levosimendan infusion was stopped. Conclusions Levosimendan infusion in cardiogenic shock following acute myocardial infarction improved cardiovascular hemodynamics without leading to hypotension.
No takes yet. Share an insight, caveat, or question.
Ruß et al. (2007) conducted an observational in Cardiogenic shock secondary to acute myocardial infarction (n=56). Levosimendan vs. Conventional catecholamine therapy (norepinephrine and dobutamine) / pre-levosimendan baseline was evaluated on Hemodynamic parameters including cardiac index, cardiac power index, and systemic vascular resistance (p=< .01). Adding levosimendan in refractory post-MI cardiogenic shock increased cardiac index and cardiac power index without hypotension.
Synapse has enriched 10 related papers. Consider them for comparative context: